Get started
Work

Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells.

Year: 2026
Type: preprint
DOI: 10.21203/rs.3.rs-8436008/v1
Authors: James Riley, Mosha Deng, Tanishk Sinha, Meizan Lai, Shuguang Jiang, Hong Kong, Vincent Cooper, Meidi Gu, Jonah Perelman, Caimei Zhang, Chiquita Hanindya, Victor Carpio, Peter Keller, Julie Jadlowsky, Rachel Leskowitz, Stephen McKenna, Megan Four, Jesus Barranco, Natalie Cooper, Ankita Jain, Mercy Gohil, Kathleen Haines, Laura Gerique, Athena Russell, Irina Kulikovskaya, Vanessa Gonzalez, Joseph Fraietta, Gabriela Plesa, Neil Sheppard, Megan Davis, Anne Chew, Noelle Frey, Carl June, Jakub Svoboda, Elizabeth Hexner
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
Funders: Gilead Sciences, University of Pennsylvania, Atara Biotherapeutics, Incyte, UroGen Pharma, National Institutes of Health, Perelman School of Medicine, University of Pennsylvania, Kite Pharma, Pharmacyclics, National Cancer Institute
Awards: G1403651065, G1852790566, G3344108550, G3428346584, G4739483508, G5640895878, G9000000688, G9000127251, G9000138654, G9000266210
OpenAlex ID: W7127318830
Cites:
Cited by:
Related to: